SCHEMBL140229

SCHEMBL140229

CC(C)Oc1ccc2[nH]c3c(C(N)=O)cc(-c4ccc(Cl)c(Cl)c4)cc3c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 20/20 1.00
BTK Q06187 7/20 0.57
JAK1 P23458 6/20 0.57
TYK2 P29597 6/20 0.57
JAK3 P52333 6/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL140338 0.81 JAK2 (0.69) JAK2BTKJAK1TYK2JAK3
SCHEMBL140096 0.79 JAK2 (0.65) JAK2BTKJAK1TYK2JAK3
SCHEMBL143613 0.76 JAK2 (0.79) JAK2BTKJAK1TYK2JAK3
SCHEMBL142893 0.75 JAK2 (0.68) JAK2BTKJAK1TYK2JAK3
SCHEMBL13284179 0.75 JAK2 (0.84) JAK2BTKJAK1TYK2JAK3
SCHEMBL141825 0.75 JAK2 (0.80) JAK2BTKJAK1TYK2JAK3
SCHEMBL178682 0.74 JAK2 (0.80) JAK2BTKJAK1TYK2JAK3
SCHEMBL145688 0.73 JAK2 (0.81) JAK2BTKJAK1TYK2JAK3
SCHEMBL15800311 0.73 JAK2 (0.59) JAK2BTKJAK1TYK2JAK3
SCHEMBL147444 0.73 JAK2 (1.00) JAK2BTKJAK1TYK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102325752-B Carbazole and carboline kinase inhibitors BRISTOL MYERS SQUIBB CO 2015-02-04 CN claimed
CN-102325752-B Carbazole and carboline kinase inhibitors BRISTOL MYERS SQUIBB CO 2015-02-04 CN disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 JAK2 1/4885BTK 79/4885JAK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.